Inhibitors of the epidermal growth factor receptor tyrosine kinase (EGFR-TKI), has gained widespread acceptance for the treatment of metastatic EGFR-mutant non-small cell lung cancer (NSCLC), leading to notable improvements in outcomes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.